Cargando…

Anticoagulant Effects of Dabigatran on Coagulation Laboratory Parameters in Pediatric Patients: Combined Data from Five Pediatric Clinical Trials

Background Dabigatran etexilate, a direct oral thrombin inhibitor, is approved to treat venous thromboembolism (VTE) in both adults and children. Objectives This population analysis characterized relationships between dabigatran total plasma concentrations and coagulation laboratory parameters (ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mitchell, Lesley G., Röshammar, Daniel, Huang, Fenglei, Albisetti, Manuela, Brandão, Leonardo R., Bomgaars, Lisa, Chalmers, Elizabeth, Halton, Jacqueline, Luciani, Matteo, Joseph, David, Tartakovsky, Igor, Gropper, Savion, Brueckmann, Martina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2022
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420551/ https://www.ncbi.nlm.nih.gov/pubmed/35909257 http://dx.doi.org/10.1055/s-0042-1744542

Ejemplares similares

Design and rationale for the DIVERSITY study: An open‐label, randomized study of dabigatran etexilate for pediatric venous thromboembolism
por: Albisetti, Manuela, et al.
Publicado: (2018)

Pharmacokinetic modeling and simulation support for age‐ and weight‐adjusted dosing of dabigatran etexilate in children with venous thromboembolism
por: Röshammar, Daniel, et al.
Publicado: (2021)

Phase 3, single‐arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: Rationale and design
por: Luciani, Matteo, et al.
Publicado: (2018)

Anticoagulant Effects of Dabigatran in Paediatric Patients Compared with Adults: Combined Data from Three Paediatric Clinical Trials
por: Maas, Hugo, et al.
Publicado: (2018)

Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolism
por: Albisetti, Manuela, et al.
Publicado: (2017)

Dabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia
por: Brandão, Leonardo R., et al.
Publicado: (2022)

Effects of direct oral anticoagulants dabigatran and rivaroxaban on the blood coagulation function in rabbits
por: Yin, Lu, et al.
Publicado: (2022)

Direct oral anticoagulants in pediatric venous thromboembolism: Review of approved products rivaroxaban and dabigatran
por: Al-Ghafry, Maha, et al.
Publicado: (2022)

Promise and challenges of anticoagulation with dabigatran
por: Verma, Ashish, et al.
Publicado: (2012)

Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran
por: Kim, Jong-Min, et al.
Publicado: (2022)

Anticoagulant Related Nephropathy Induced by Dabigatran
por: Sharfuddin, Nazia, et al.
Publicado: (2018)

New options with dabigatran etexilate in anticoagulant therapy
por: Maegdefessel, Lars, et al.
Publicado: (2010)

Features of Pharmacodynamics of the Anticoagulant Dabigatran in Secondary Thrombophilia
por: Kairov, Gaisa T., et al.
Publicado: (2018)

Delayed concentration effect models for dabigatran anticoagulation
por: Eaton, Michael P., et al.
Publicado: (2022)

Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran
por: Glund, Stephan, et al.
Publicado: (2019)

Impact of Antithrombin Supplementation and Concomitant Anticoagulation Therapy in Pediatric Patients With Disseminated Intravascular Coagulation
por: Nagafuchi, Hiroyuki, et al.
Publicado: (2019)

Specific Point-of-Care Testing of Coagulation in Patients Treated with Dabigatran
por: Härtig, Florian, et al.
Publicado: (2021)

Practical considerations on anticoagulation reversal: spotlight on the reversal of dabigatran
por: Giannandrea, David, et al.
Publicado: (2019)

Monitoring of Anticoagulant Activity of Dabigatran and Rivaroxaban in the Presence of Heparins
por: Jakimczuk, Aleksandra, et al.
Publicado: (2022)

International pediatric thrombosis network to advance pediatric thrombosis research: Communication from the ISTH SSC subcommittee on pediatric and neonatal thrombosis and hemostasis
por: van Ommen, C. Heleen, et al.
Publicado: (2021)

Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran
por: Sié, Pierre
Publicado: (2016)

A novel oral anticoagulant, dabigatran, in acute renal infarction
por: Altın, Cihan, et al.
Publicado: (2015)

Safety of Dabigatran as an Anticoagulant: A Systematic Review and Meta-Analysis
por: Zhou, Ya, et al.
Publicado: (2021)

Effects of Simvastatin on Pharmacokinetics and Anticoagulant Effects of Dabigatran in Healthy Subjects
por: Chung, Hyewon, et al.
Publicado: (2023)

Design and Rationale of the RE‐DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting
por: Cannon, Christopher P., et al.
Publicado: (2016)

Anticoagulant therapy in pediatrics
por: Dabbous, Mariam K., et al.
Publicado: (2014)

Effect of Oral Anticoagulant Therapy on Coagulation Activity and Inflammatory Markers in Patients with Atrial Fibrillation Undergoing Ablation: A Randomized Comparison between Dabigatran and Warfarin
por: Amini, Shahideh, et al.
Publicado: (2013)

Antithrombotic Therapy in a Prospective Trial of a Pediatric Ventricular Assist Device
por: Steiner, Marie E., et al.
Publicado: (2016)

In Vitro Selection of Specific DNA Aptamers Against the Anti-Coagulant Dabigatran Etexilate
por: Aljohani, Maher M., et al.
Publicado: (2018)

Effects of dabigatran and rivaroxaban on stroke severity according to the results of routine coagulation tests
por: Cho, Han-Jin, et al.
Publicado: (2020)

Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate
por: Bellamy, L, et al.
Publicado: (2009)

No Influence of Dabigatran Anticoagulation on Hemorrhagic Transformation in an Experimental Model of Ischemic Stroke
por: Bohmann, Ferdinand, et al.
Publicado: (2012)

Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation
por: Choi, Jiyoon C, et al.
Publicado: (2014)

Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation
por: Grottke, Oliver, et al.
Publicado: (2016)

Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal
por: Proietti, Marco, et al.
Publicado: (2018)

Dental management of patients taking novel oral anticoagulants (NOAs): Dabigatran
por: Curto, Adrian, et al.
Publicado: (2017)

Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients
por: Úlehlová, Jana, et al.
Publicado: (2021)

Effects of uninterrupted dabigatran on the intensity of anticoagulation during atrial fibrillation ablation
por: Osawa, Takumi, et al.
Publicado: (2021)

Electrochemical Disposable Biosensor to Monitor Dabigatran in Point-of-Care Anticoagulation Therapy
por: Mruthunjaya, Ashwin K. V., et al.
Publicado: (2023)

Novel Coagulation Test Detects Anticoagulation Resistance and Is Associated With Thrombotic Events in Pediatric Patients Requiring Extracorporeal Membrane Oxygenation
por: Frydman, Galit H., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_58nun52gl0jldtko83dsb25u23